MBX Biosciences, Inc.
MBX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$52.97
KIRA · Stoqly’s AI analyst, in plain words
- MBX Biosciences, Inc. lost $87.0M in fiscal 2025.
- Free cash flow was −$81.9M in fiscal 2025, — of revenue.
Market cap
$2.5B
P/E
—
Revenue
—
Net income
−$87.0M
Free cash flow
−$81.9M
Operating margin
—
MBX Biosciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$87.0M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What MBX Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- MBX Biosciences, Inc.
- CIK
- 0001776111
MBX Biosciences, Inc. · MBX
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$32.6M | −$61.9M | −$87.0M |
| Diluted EPS | −$31.96 | −$5.82 | −$2.38 |
| Cash | |||
| Cash from operations | −$32.0M | −$54.7M | −$79.9M |
| Capital expenditure | $0.1M | $0.9M | $1.9M |
| Free cash flow | −$32.1M | −$55.6M | −$81.9M |
| Share count change | — | 944.7% | 243.0% |
| Debt and strength | |||
| Cash and short-term investments | $80.7M | $262M | $374M |
| Shareholders' equity | −$72.5M | $257M | $369M |
| Current ratio | 21.3x | 24.2x | 24.6x |
| Returns and quality | |||
| Return on equity | — | −67.0% | −27.8% |
| Return on tangible equity | — | −24.1% | −23.6% |
| Altman Z'' | −17.3 | 27.3 | 27.0 |
Insiders bought, 12 months
$0.5M
1 insider
Insiders sold, 12 months
$2.7M
2 insiders
Of sales under plans
98%
$2.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
MBX Biosciences, Inc. · MBX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $52.97 a share, the company is worth $2.5B.
Source: SEC EDGAR XBRL filings (CIK 0001776111). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.